Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael M Meagher

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Microbial Cell Factories|November 25, 2010
Fed-batch fermentation of GM-CSF-producing glycoengineered Pichia pastoris under controlled specific growth ratePieter P Jacobs, Mehmet Inan, Nele Festjens, et al.
Protein Expression and Purification|December 19, 2003
Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastorisScott K Johnson, Wenhui Zhang, Leonard A Smith, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Crystallization and preliminary X-ray analysis of Na-ASP-1, a multi-domain pathogenesis-related-1 protein from the human hookworm parasite Necator americanusOluwatoyin A Asojo, Alex Loukas, Mehmet Inan, et al.
Molecular Therapy. Methods & Clinical Development|April 13, 2016
Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vectorBryan A Piras, Jason E Drury, Christopher L Morton, et al.
Mabs|July 10, 2020
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumorsMichael W Bishop, Paul R Hutson, Jacquelyn A Hank, et al.
Protein Expression and Purification|October 12, 2010
Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastorisMichael P Dux, Jicai Huang, Rick Barent, et al.
Journal of Biotechnology|October 3, 2006
Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBoNTE(H(c)): antigen E) by Pichia pastorisJayanta Sinha, Mehmet Inan, Sarah Fanders, et al.
Protein Expression and Purification|October 11, 2005
Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115Michael P Dux, Rick Barent, Jayanta Sinha, et al.
Biotechnology Progress|June 2, 2011
Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc™Michael M Meagher, Javier G Seravalli, S Todd Swanson, et al.
Blood|April 25, 2021
The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspectiveNancy S Bolous, Yichen Chen, Huiqi Wang, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Microbial Cell Factories|November 25, 2010
Fed-batch fermentation of GM-CSF-producing glycoengineered Pichia pastoris under controlled specific growth ratePieter P Jacobs, Mehmet Inan, Nele Festjens, et al.
Protein Expression and Purification|December 19, 2003
Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastorisScott K Johnson, Wenhui Zhang, Leonard A Smith, et al.
Acta Crystallographica. Section F, Structural Biology and Crystallization Communications|March 3, 2006
Crystallization and preliminary X-ray analysis of Na-ASP-1, a multi-domain pathogenesis-related-1 protein from the human hookworm parasite Necator americanusOluwatoyin A Asojo, Alex Loukas, Mehmet Inan, et al.
Molecular Therapy. Methods & Clinical Development|April 13, 2016
Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vectorBryan A Piras, Jason E Drury, Christopher L Morton, et al.
Mabs|July 10, 2020
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumorsMichael W Bishop, Paul R Hutson, Jacquelyn A Hank, et al.
Protein Expression and Purification|October 12, 2010
Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastorisMichael P Dux, Jicai Huang, Rick Barent, et al.
Journal of Biotechnology|October 3, 2006
Cell bank characterization and fermentation optimization for production of recombinant heavy chain C-terminal fragment of botulinum neurotoxin serotype E (rBoNTE(H(c)): antigen E) by Pichia pastorisJayanta Sinha, Mehmet Inan, Sarah Fanders, et al.
Protein Expression and Purification|October 11, 2005
Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115Michael P Dux, Rick Barent, Jayanta Sinha, et al.
Biotechnology Progress|June 2, 2011
Process development and cGMP manufacturing of a recombinant ricin vaccine: an effective and stable recombinant ricin A-chain vaccine-RVEc™Michael M Meagher, Javier G Seravalli, S Todd Swanson, et al.
Blood|April 25, 2021
The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspectiveNancy S Bolous, Yichen Chen, Huiqi Wang, et al.
Pageof 4